Cala Health

What Cala Health does

Cala Health is a bioelectronic medicine company that develops wearable neuromodulation devices for the treatment of chronic diseases, with a current commercial focus on action hand tremor in adults with essential tremor (ET) and Parkinson's disease (PD). Founded in 2014 as a spinout from Stanford Biodesign and headquartered in San Mateo, California, the company has built its commercial offering around a proprietary therapy called TAPS (Transcutaneous Afferent Patterned Stimulation), a non-invasive peripheral-nerve-stimulation modality delivered through a wrist-worn device that stimulates the median and radial nerves to reduce tremor. The product line has progressed through four device generations — Cala One, Cala Trio, the Cala kIQ System, and the Cala kIQ Plus — each cleared by the FDA under De Novo or 510(k) pathways and supported by the MyCala cloud-connected patient portal, with regulatory milestones including FDA De Novo authorization (DEN170028, 2018), FDA Breakthrough Device Designation for PD (2020), and a Medicare Local Coverage Determination (L39591, 2024). Clinical evidence includes the prospective PROSPECT study, a 310-patient real-world dataset developed with CVS Health, and reported outcomes of 92% in-session tremor improvement, 71% average reduction in tremor power, and 64% persistent relief with repeated use.

The company operates a hybrid direct-to-patient and B2B2C commercial model: the device is shipped direct-to-home after prescription verification, supported by a provider channel targeting movement-disorder neurologists, a dedicated Veterans Affairs channel, and a telehealth evaluation partnership with Neurahealth. Revenue is generated through hardware sales of the controller device and a recurring consumable stream from replacement stimulator bands required roughly every 90 days, with reimbursement secured through Medicare (LCD L39591 plus HCPCS codes A4593, A4594, E0734), commercial insurance, and the VA. Cala has accumulated a portfolio of 16+ US patents covering the TAPS platform and has raised approximately $298M+ across multiple equity and structured-debt rounds between 2014 and 2026, with investors including Ascension Ventures, Vertex Growth Fund, Nexus NeuroTech Ventures, Niterra Ventures, Trinity Capital, Johnson & Johnson Innovation, Google Ventures, Lightstone Ventures, Lux Capital, and Baird Capital.

Name

Cala Health

Legal name

Cala Health, Inc.

Website

https://calahealth.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

101–250 employees

Short description

Cala Health is a bioelectronic medicine company that develops FDA-cleared wrist-worn TAPS neuromodulation devices delivering non-invasive therapy for action hand tremor in adults with essential tremor and Parkinson's disease, reimbursed by Medicare, the VA, and commercial insurers.

Ownership category

akta.pro rank

Product category

Wearable Neuromodulation Therapy Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Rehabilitation Therapy Equipment (PT/OT Modalities, Exercise & Balance Devices) (HLAHAMAG)

akta.pro secondary industries

Digital Rehabilitation & Physical Therapy Therapeutics (HLACANAJ), Neurologic Rehabilitation (Stroke, TBI, Parkinson’s, MS) (HSADAIAC), Chronic Pain Rehabilitation & Functional Restoration (HSADAIAJ)

Keywords

• Wearable neuromodulation devices
• Peripheral nerve stimulation
• Essential tremor therapy
• Neuromodulation medical devices
• Bioelectronic medicine

Headquarters

HQ city

San Mateo

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Cala kIQ / Trio device hardware sales: One-time sale of the wrist-worn TAPS neurostimulation controller (Cala kIQ or Cala Trio). Device revenue is recognized at the time of shipment to the patient or provider.
2. Replacement stimulator-band subscription: Recurring consumable revenue: replaceable stimulating bands must be swapped roughly every 90 days. Band-only replenishment creates a predictable subscription-like revenue stream attached to each active patient.
3. Reimbursement revenue (Medicare, commercial insurance, VA): Cala Health bills Medicare (under the LCD covering essential tremor), commercial insurers, and the Veterans Health Administration for the device and bands. Most patients pay a 20% coinsurance under Medicare.

Pricing tiers

Go-to-market motion5 records

Distribution channels5 records

Marketing channels8 records

Core offering

Cala Health develops and sells FDA-cleared, wrist-worn wearable neuromodulation devices (Cala kIQ System and Cala kIQ Plus) that deliver its proprietary TAPS (Transcutaneous Afferent Patterned Stimulation) therapy to provide temporary relief of action hand tremor in adults with essential tremor and Parkinson's disease. The company also supplies recurring replacement stimulating bands (~every 90 days) and operates a cloud-connected MyCala patient portal for therapy tracking and onboarding.

Product overview

Cala Health's offering is a single, platform-plus-modules architecture built around one therapeutic modality — Cala TAPS (Transcutaneous Afferent Patterned Stimulation) — delivered through successive generations of FDA-cleared wrist-worn wearable neuromodulation devices: the still-supported first-generation Cala One and second-generation Cala Trio, the current flagship Cala kIQ System, and the newly cleared next-generation Cala kIQ Plus. Therapy data from these devices is uploaded via LTE to the companion MyCala.com Patient Portal, which functions as the patient-facing data and onboarding module, while a Clinical Evidence Library and a prescription kit serve as the provider-facing modules that complement the core device platform.

Differentiator

Problem solved

Functional benefit

Brands

• Cala kIQ: Cala's current-generation FDA-cleared wrist-worn wearable therapy system that delivers TAPS therapy for action hand tremor in essential tremor and Parkinson's disease.
• Cala kIQ Plus
• Cala Trio
• Cala TAPS

Products and services

• Cala kIQ System FDA-cleared wrist-worn wearable neuromodulation device that delivers Cala TAPS therapy to adults with essential tremor and Parkinson's disease; physician-prescribed, used at home on demand.
• Cala kIQ Plus Next-generation FDA-cleared wrist-worn wearable neurostimulation device delivering TAPS therapy for action hand tremor in essential tremor and Parkinson's disease patients; introduced as the successor to the Cala kIQ System.
• Cala Trio Second-generation Cala Health wearable delivering TAPS therapy for the temporary relief of hand tremors in adults with essential tremor and Parkinson's disease; still supported as a legacy generation device.
• Replacement Stimulator Bands Replaceable stimulating bands for the Cala kIQ and Cala Trio wearables, replenished on roughly a 90-day cadence; constitutes a recurring consumable revenue stream attached to each active patient.
• MyCala Patient Portal Cloud-based patient portal paired with the Cala kIQ device that receives session data over LTE, tracks tremor history and session logs, hosts onboarding/training resources, and supports prescription fulfillment.

Quantifiable outcome

• 92% of patients showed tremor improvement during a TAPS therapy session.
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature6 records

Partnerships

Four partnerships are on record, tiered flagship strategic partnership, flagship academic partnership, core ip/licensing relationship and core telehealth channel.

• SK Biopharmaceuticalsflagship strategic partnershipStrategic or Co-development Partner · 18 May 2022Announced May 18, 2022: Cala Health partnered with SK Biopharmaceuticals to fuel innovation in neurology. SK Biopharmaceuticals is a global pharma company focused on CNS therapeutics; partnership aimed at advancing Cala's wearable neuromodulation pipeline.
• University of California, San Francisco (UCSF)flagship academic partnershipStrategic or Co-development Partner · 17 June 2021Announced June 17, 2021: Cala Health and UCSF announced a partnership to develop next-generation, smart neuromodulation therapies. Joint research effort aimed at advancing wearable neuromodulation for tremor and other neurology indications.
• Partners HealthCare (Massachusetts General Hospital / Brigham and Women's)core ip/licensing relationshipOEM/ Whitelabel/ Licensing Partner · 11 March 2019Announced March 11, 2019: Cala Health licensed innovative technology from Partners HealthCare to develop and deliver novel therapies for patients with chronic disease. The licensed IP underlies Cala's TAPS peripheral-nerve-stimulation platform.
• Neurahealthcore telehealth channelChannel Partner/ Reseller/ DistributorTelehealth partner enabling online evaluation by a movement-disorder neurologist; patients can obtain a Cala prescription via Neurahealth without an in-person visit.

Scale indicators13 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• ElectroCore: Developer of non-invasive vagus nerve stimulation (nVNS) devices (gammaCore) for headache, migraine, and other neurological conditions. Closely comparable as a wearable, prescription-based, FDA-cleared neurostimulation company pursuing non-invasive alternatives to drugs and invasive stimulation.
• NeuroPace: Developer of the RNS System, a closed-loop responsive neurostimulator for refractory epilepsy. Comparable as a small, venture-backed neurostimulation company targeting chronic neurological conditions with a similar mix of clinical evidence and reimbursement milestones.

Broad incumbents

• Boston Scientific (Vercise DBS): Sells the Vercise deep brain stimulation system for Parkinson's disease. A broad medtech incumbent competing in the same tremor patient population as Cala.
• Medtronic (Activa DBS): Long-standing leader in deep brain stimulation systems (Activa) for movement disorders including ET and PD. Represents the dominant surgical neuromodulation option in Cala's competitive landscape.
• Abbott (Infinity DBS): Markets the Infinity deep brain stimulation system for Parkinson's disease and essential tremor. Comparable as the incumbent invasive alternative that Cala explicitly positions against for tremor patients.
• LivaNova (VNS Therapy): Markets Vagus Nerve Stimulation (VNS Therapy) for epilepsy and treatment-resistant depression. A long-standing neuromodulation incumbent with a similar regulatory-and-reimbursement-driven commercial approach.
• INSPIRE Medical Systems: Implantable neurostimulation company (Inspire) for obstructive sleep apnea. Comparable as a high-growth, prescription-based neurostim company targeting a chronic condition with a similar payor-driven commercial model.
• Axonics (now part of Boston Scientific): Sacral and pudendal neuromodulation implants for incontinence. A successful mid-cap neuromodulation company with a recurring implant-and-replace commercial model, broadly comparable in therapeutic neurostimulation.

Emerging players

• Fisher Wallace: Markets wearable cranial electrotherapy stimulation devices for depression, anxiety, and insomnia. Comparable as a smaller, consumer-adjacent non-invasive neurostimulation company targeting chronic conditions with a prescription wearable.
• MindMaze: Digital therapeutics and neurorehabilitation platform combining gamified software and hardware for stroke and brain injury recovery. Comparable as a digitally-enabled neurorehabilitation therapy targeting similar patient populations (stroke, movement disorders).

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCsgfuuoK515MGu3QP0LOGHA
• Facebookfacebook.com/CalaHealth
• LinkedInlinkedin.com/company/cala-health-inc
• Xx.com/calahealth

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds8 records

Investors28 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cala Health